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ABSTRACT 
Objective: To assess the quality of life and psychosocial well-being of brain tumour 
patients and their carers.  
Methods: A cross-sectional postal survey was completed by 75 patients and 70 carers 
(response rate 29.8%) who were listed on a community-based brain tumour support 
group database. Measures were the Functional Assessment of Cancer Therapy 
(FACT-G) and the Hospital Anxiety and Depression Scale (HADS). Queensland 
population-based norms for the FACT-G were used for comparison.  
Results: On average compared to population norms, FACT-G summary scores of 
patients (mean = 74.6, SD =18.6) and carers (mean = 76.7, SD = 17.7) were between 
one half and one standard deviation lower, representing a clinically significant 
reduction in quality of life. Among patients and carers, 30% and 40% reported 
anxious mood and 17% and 10% depressed mood on the HADS, respectively. 
Significant correlations were observed between FACT-G and HADS subscales, in 
particular emotional well-being and anxiety, as well a physical and functional well-
being and depression, and between patients’ and their carers’ quality of life. Among 
patients, predictors of lower quality of life were older age and female gender, whereas 
for carers there was a trend for lower quality of life among those looking after a 
patient with high-grade disease.  
Conclusions: The degree of detriment to quality of life by a brain tumour for both 
patients and their carers is similar and clinically significant. The association between 
the FACT-G subscales and the HADS indicate that improvements could be achieved 
by alleviating emotional distress and improving functional well-being.  
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Introduction 
The last 20 years have seen advances in the treatment and outcomes for patients with 
a brain tumour. These include refinements of surgical techniques, introduction of new 
chemo- and radio-therapeutic regimens such as temozolomide for glioma and trials of 
novel biologic therapies [1, 2]. However, due to their anatomical location, most brain 
tumours increase the intracranial pressure and displace healthy brain tissue, thus 
resulting in temporary or permanent disruptions to the associated executive functions, 
and overall survival is till poor [1] and some centres did not observe a beneficial trend 
in prognosis among patients with high- or low-grade gliomas [3] . 
Due to the severity of disease and subsequent focus on improving survival, quality of 
life and psychosocial well-being of survivors of brain tumours have only more 
recently received attention [4].  Frequently, self-reported quality of life does not 
correlate well with measures of physical or neurological functioning such as the 
Karnofsky Performance Scale [5, 6], leading to the development of brain tumours 
specific quality of life scales [5, 7]. For example, the Functional Assessment of 
Cancer Therapy- General (FACT-G) is one of the most widely used quality of life 
assessment instruments in cancer research [8, 9] and recently general population 
based norms have also become available [10]. A brain tumour specific quality of life 
subscale to accompany the FACT-G was developed in 1995 [7]. Using this brain 
tumour specific instrument, comparatively good quality of life among samples of 
brain tumour patients has been reported in some studies [7], while other studies noted 
significant reductions in quality of life among patients treated for a brain tumour [5, 
11]. Up to 90% of brain tumour patients self-report morbidity in one and 70% in two 
or more health attributes such as cognition, mobility, vision, hearing, speech or pain, 
with more severe reductions in quality of life found to be associated with early 
mortality from a brain tumour [12]. This is in line with several other studies, which 
demonstrated diminished survival prospective among brain tumour patients with 
depressed mood or changes in mental status – in particular among patients with low 
grade disease [13-16], and consistently, higher scores of depression were associated 
with lower quality of life [17-19]. However, to date, most research on the quality of 
life of patients with a brain tumour was conducted using clinic derived samples, thus 
little is known about the quality of life and mood among community dwelling patients 
with a brain tumour.  
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While some patients with a brain tumour will make a complete recovery after 
treatment, most will require at least some support and care in subsequent years [20, 
21]. Care is primarily provided by relatives and friends and few cancer patients rely 
solely on formal care [22, 23]. Stress associated with caregiving can be considerable, 
and this has been shown to impact on quality of life in various carer populations, 
including carers of patients with Alzheimer’s disease, cancer in general and brain 
tumours in particular [22-26]. Patients and carers quality of life has been shown to be 
closely associated among breast and colorectal cancer survivors [27-29]. Earlier, we 
identified a number of unmet supportive care needs which may result in reductions in 
quality of life of patients with a brain tumour and their and carers [30].  
To extend the knowledge about how patients living in the community and their carers 
fare in the medium to long term, the present study aimed to describe the quality of life 
and psychosocial well-being of patients with a brain tumour and their carers who 
subscribed to a dedicated brain tumour support network. A further aim was to 
compare the quality of life of patients with a brain tumour and their carers to 
population norms and to assess factors associated with low quality of life. 
 
 
Methods 
Approval for this study was obtained from the Behavioral and Social Sciences 
Research Ethical Review Committee of the University of Queensland, Australia.  
The Queensland Cancer Fund is a community-based not-for-profit organisation 
serving the Queensland population with cancer related information and support 
services. One of these services is a Brain Tumour Support Service which provides 
information about brain tumours, treatment, support agencies, rehabilitation services 
and practical assistance. The service holds regular meetings for patients, carers and 
health professionals interested in brain tumours at which a specific topic is presented 
and discussed by a health professional; provides opportunities for peer support 
through discussions with other people who have been affected by a brain tumour; and 
distributes quarterly newsletters. 
Overall, 363 survey packages (containing a study information sheet, and patient and 
carer questionnaires) were mailed to current members of the Brain Tumour Support 
Service. Overall, of 363 survey packages mailed, 48 were returned to sender or 
returned with a note that the patient was deceased. After two written reminders, at 
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least one completed questionnaire was received from 94 households resulting in an 
overall response rate of 29.8%. Among the 94 households, 75 patients and 73 carers 
returned completed questionnaires. Of those, 53 patients-carer pairs from the same 
household responded, while within 23 households only the patient and within 20 
households only the carer responded.  
Measures  
Patients and carers were asked to report on their own demographic details, quality of 
life and psychosocial well-being. The only exception from this was the questions 
about details of the brain tumour diagnosis and treatment where carers were asked to 
report on the patient’s medical details. 
Demographic and health characteristics: Patients and carers were asked to give their 
age, sex, education, work status, marital status, the number of children in the 
household, income and number of people dependent on that income. Patients and 
carers self-reported on the date of diagnosis of brain tumour, if the tumour was benign 
or malignant, type of tumour, and treatment received, as well as date of last treatment.   
Quality of life: The Functional Assessment of Cancer Therapy was used to assess 
patients’ and carers’ own quality of life [8, 9]. Patients also completed a brain tumour 
specific subscale, which together with the FACT-General forms the FACT-Brain 
(FACT-BR) [7]. Carers completed the general population version of the FACT, 
(FACT-GP), which can be prorated to result in scores equivalent to the FACT-G. All 
questions are answered on a 5-point Likert-scale ranging from “not at all” to “very 
much”. The FACT-G allows generation of 4 subscales indicating participants’ 
physical well-being (range 0-28), social well-being (range 0-28), emotional well-
being (range 0-24), and functional well-being (range 0-28), as well as the FACT-G 
summary score (0-108). Adding the brain tumour specific subscale for patients results 
in the FACT-Br score (range 0-160). Higher scores indicate better quality of life. 
Test-retest reliability for the FACT-Br was reported to be 0.78, and good convergent 
validity has also been reported for the FACT-Br [7]. Within the present sample, 
Chronbach alpha for the FACT-G among the patient group was 0.92, and 0.88 for 
carers. 
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Psychological Well-being: The Hospital Anxiety and Depression scale (HADS) was 
used to measure psychological distress in patients and carers. The HADS is a well 
validated questionnaire suitable for cancer populations as it contains only non-
physical symptoms of both anxiety and depression, and has also been used 
extensively in non-clinical populations [31-34]. Participants indicate their agreement 
with each item on 4-point Likert scales with various anchors. According to scoring 
instructions, seven items are recoded and summarised to form the depression scale 
(range 0-21) and seven items form the anxiety scale (range 0-21). Participants who 
score 8-10 on either sub-scale are considered doubtful cases and those who score 11 
or higher are considered cases with regards to anxiety or depression [32]. 
 
Statistical analysis 
Descriptive analysis was undertaken to summarise patients’ and carers’ demographics 
and patients’ health characteristics. It was expected that among members of the 
support service, patients with low-grade tumours would be overrepresented. To allow 
adjustment for this, all patient data were weighted using the 20-year prevalence of 
brain tumours by morphological subgroups in Queensland. Comparison with 
normative FACT-G quality of life data for the Queensland population was undertaken 
and patient and carers scores plotted against t-distributed normative scores. As 
recommended previously [10, 35], a diversion of ½ a standard deviation or more was 
regarded as a clinically significant difference from the normative score. Pearson 
correlations were used to assess correlation of quality of life, anxiety and depression 
reported among the 53 patient-carer pairs. Associations between quality of life and the 
HADS among patients and carers separately were also investigated utilising Pearson 
correlations. Patients’ and carers’ quality of life scores were then dichotomised where 
a clinical significant deviation from the population norms was observed (in other 
words, patients and carers were divided into 2 groups each, characterised by quality of 
life similar to the population and quality of life clinically significantly below the 
general population). Variables that were associated with quality of life in bivariate 
logistic regression were entered into a multivariate logistic regression analysis; non-
significant variables were removed to achieve the most parsimonious model while 
retaining the best fit.  
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Results 
Overall, of 363 survey packages mailed, 48 were returned to sender or returned with a 
note that the patient was deceased. After two written reminders, at least one 
completed questionnaire was received from 94 households resulting in an overall 
response rate of 29.8%. Among the 94 households, 75 patients and 70 carers returned 
completed questionnaires. Of those, 53 patients-carer pairs from the same household 
responded. Patients and carers reported on their own demographic characteristics, 
quality of life and mood. Carers were asked to report on the medical details of the 
patient with a brain tumour they were caring for. 
 
The majority of participants in both groups were women (54.1% of patients and 
64.3% of carers), and 53.5% of patients and 43.1% of carers were younger than 50 
years. Other demographic details are listed in Table 1. The most common tumour 
morphologies reported by patients and carers were meningioma, glioblastoma and 
astrocytoma, and 58.7% of patients and 71.0% of carers self-reported the brain 
tumour to be malignant.  Most patients had received a combination of two or more 
treatments, most commonly surgery followed by radiotherapy. More than 70% of 
patients had received their last treatment within the past year and a similar percentage 
of treatment within the past year was reported by the carers (Table 1). 
 
FACT-G subscale and overall scores as well as HADS scores for patients and carers 
are reported in Table 2. Among the 53 patient-carer pairs living in the same 
household, significant correlations were found between patients’ and carers’ 
emotional and social well-being as well as overall quality of life but not between 
patients’ and carers’ physical or functional well-being. Reductions in several aspects 
of quality of life by ½ a standard deviation or more compared to the Queensland 
population were observed (Figure 1).  Patients’ overall quality of life as measured by 
the FACT-G was clinically significantly lower compared to the general population 
driven by low scores within the physical, emotional and function well-being 
subscales. Carers’ overall quality of life, although 3 points higher than that of patients 
on average, was also clinically significantly lower than the quality of life among the 
general Queensland population, again driven mainly by reductions in the physical, 
emotional and function well-being subscales. Among the quality of life subscales in 
patients, low emotional well-being was most closely associated with anxiety, while 
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low physical and functional well-being was associated with depression. Similarly, in 
carers highest correlation coefficients were observed between low emotional well-
being and anxiety as well as low functional well-being and depression (Table 3).  
 
In bivariate analysis among patients, female gender (OR 5.8, 95% CI 1.8-18.1), age 
50  years or older  (OR = 2.6, 95% CI 0.94-7.4) were associated with lower quality of 
life, while no difference was found by education, current employment status, marital 
status, income, time since diagnosis, self-reported malignancy of the tumour, tumour 
morphology, or time since treatment. In multivariate logistic regression analysis, 
female gender and age 50 years and over remained significant predictors of low 
quality of life in patients when adjusting for tumour type (Table 4).  
For carers, responsibility for a patient with a glioblastoma was associated with low 
quality of life in univariate analysis (OR= 6.7; 95% CI 1.8-25.2). In the adjusted 
analysis, there was some indication of better quality of life among older carers. There 
was a trend for carers who looked after a patient with glioblastoma to report low 
quality of life compared to carers looking after patients with other tumours (Table 4). 
 
Discussion 
This study suggests that on average, both patients with a brain tumour and their carers 
live with a clinically significant reduction in their overall quality of life compared to 
the general population. This finding holds true irrespective of the time since diagnosis 
or the time since last treatment. Among patients, women and older patients appear to 
be more susceptible to reductions in quality of life, while among carers, the burden of 
looking after a patient with glioblastoma has the greatest impact on quality of life. 
Preoperatively, quality of life has been reported to be worse in patients with highly 
malignant tumours as well as those with tumours located in the right hemisphere or in 
the anterior cortex compared with left hemisphere or posterior tumours [36, 37]. Also 
among a group of newly diagnosed high-grade glioma patients, quality of life scores 
(measured by the FACT-Br and a linear analogue scale) were found to be predictive 
of survival [38]. Klein et al. assessed quality of life using the SF-36 health survey to 
compare the quality of life among 68 newly diagnosed patients with glioma to general 
population norms and reported significant reductions of quality of life within all 
domains [39].  
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Similar to other studies within the present investigation, few predictors of reduced 
quality of life among patients were found [7, 38]. Apart from depression and anxiety 
strongly correlated with quality of life in this and others studies [14, 15, 18, 40], 
female gender was the only predictor of low quality of life in our study also reported 
by others [41, 42]. There was no apparent difference in quality of life depending on 
self-reported tumour histology, time since diagnosis or last treatment, again similar to 
results reported by others [43]. This indicates that living with a diagnosis of a brain 
tumour can be difficult for patients and their carers irrespective of the malignancy of 
the disease. This is further supported by the magnitude of detriment in quality of life 
observed among the patients and carers in our study when compared to the general 
population of Queensland. On the other hand, within the present study we did not 
measure other factors such as dispositional optimism, coping approaches or social 
support which could potentially explain some of the variance in patients’ and carers’ 
quality of life observed.  
 
The finding that carers looking after a patient with high grade malignancies such as 
glioblastoma were somewhat more likely to report lower quality of life is likely to 
reflect the high burden associated with caring for family members with frequent and 
complex care needs. A significant number of these patients will be affected by neuro-
psychological deficits, fatigue and pain which often parallel advancing disease [6, 43]. 
During focus groups and qualitative interviews carers of patients with a brain tumour 
reported that caring had a significant impact of on their own well-being [30]. This is 
reflected in the significant correlation between patients and carers overall quality of 
life in this study with patients and carers in the same household reporting similar 
reductions especially in their emotional and social well-being. Similar associations 
between patients and carers well-being have been reported previously among breast 
and colorectal cancer samples [27-29], indicating that supportive care programs need 
to be directed at both the patients and their carers to effectively alleviate distress. 
 
While levels of anxiety and depression measured by the Hospital Anxiety and 
Depression Scale were high, with at least 30% of patients and carers identified as 
likely cases with elevated anxious mood, and at least 17% of patients and 10% of 
carers identified as likely cases with elevated depressed mood, they are comparable to 
those observed among other cancer populations [31, 33, 34]. In a previous study 
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among patients with a brain tumour, using a health utility instrument, up to 50% of 
patients reported emotional morbidity through anxiety [12]. Further research is 
needed to understand the physical and psychological factors associated with high 
levels of anxiety and depression in brain tumour patients and their carers as well as 
strategies for their reduction. 
 
Limitations 
Several limitations of this study must be noted. Prospective studies have highlighted 
the difficulty of collecting and interpreting data from patients with a brain tumour, 
due to a high prevalence of neurological morbidity and disease progression [38, 44]. It 
is likely that patients with more severe reductions in quality of life, as well as those 
with neuropsychological deficits will have decided not to participate in this survey.  
Also the patients and carers attending the Brain Tumour Support Service are likely to 
represent a selected group of active support seekers.  Such a group may have a higher 
prevalence of people with better quality of life and thus the resources to attend 
support groups or alternative of those with poorer quality of life who search more than 
others for support to improve their situation. Similar to other studies conducted 
among populations affected by a brain tumour, the response rate amongst the potential 
participants was low [45]. However, the calculated response rate of 29.8% may be a 
low estimate, as some of the addresses on the mailing list will have contained persons 
interested in brain tumour support in general who wished to receive the Brain Tumour 
Support Group’s correspondence, but were not necessarily a patient or carer. The fact 
that tumour morphologies reported by patients were roughly similar to the 20-year 
prevalence of brain tumours in Queensland leaves us confident that the bias through 
the low response rate should be minimal. However, another caveat when interpreting 
the results of the study is related to the brain tumour morphology and malignancy of 
the tumour, which was derived from patient and carer self-reports only and was not 
checked against medical records.  
 
A major strength of the present investigation is the comparison with population-based 
normative data for the FACT-G, which have only very recently become available in 
the USA [10] and Queensland, Australia [46] allowing comparison of patient and 
carer findings with age-matched norms. Patients’ and carers’ quality of life could 
therefore be described in the magnitude and direction in which it deviates from 
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population norms making the interpretation of this cross-sectional data much more 
meaningful. In addition, access to the 20-year prevalence data of brain tumours in 
Queensland through the Queensland Cancer Registry allowed weighting the patient 
data to the expected number of patients within each subgroup living in Queensland. 
 
In summary, the clinically significantly lower levels of quality of life observed among 
patients with a brain tumour and their carers compared to the general population and 
the association between patients’ and carers’ quality of life suggest that supportive 
care services need to be further improved to alleviate the burden this diagnosis takes 
on patients and carers. 
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Table 1 Patient (n = 75) and carer (n=70) characteristics * 
  Patients  Carers  
  n %  n %  
Sex        
Women  40 54.1 45 67.2 
Men  34 45.9 22 32.8 
Age        
Less than 50 years 38 53.5 28 43.1 
50 years and over 33 46.5 37 56.9 
Education         
University degree  20 27.0 12 17.6 
Trade/technical certificate or diploma  32 43.2 21 30.9 
Senior high school or less schooling 22 29.7 35 51.5 
Current Employment Status        
Not currently employed 46 62.2 30 44.1 
Employed part-time 9 12.2 17 25.0 
Employed full-time 19 25.7 21 30.9 
Reason for Not Working        
Looking for work 7 13.2 7 17.5 
Unable to work due to illness 25 47.2 0 0.0 
Retired/ Student 15 28.3 17 42.5 
Home carer 6 11.3 16 40.0 
Marital Status        
Married 46 62.2 55 80.9 
Living together 4 5.4 4 5.9 
Divorced/ Separated/ Widowed 12 16.2 9 13.2 
Never married 12 16.2 0 0.0 
Income        
<$20,000 22 29.3 11 16.2 
$20-40,000 15 20.0 18 26.5 
$40-60,000 12 16.0 9 13.2 
$60-80,000 10 13.3 16 23.5 
$80-100,000 3 4.0 4 5.9 
>$100,000 3 4.0 4 5.9 
Don’t know/refuse to answer 10 13.3 6 8.8 
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Table 1 continued  
  Patients  Carers  
  n %  n %  
Time since BT diagnosis      
5 years or less 29 46.0 38 55.1 
>5 to 10 years 20 31.7 17 24.6 
>10 years 14 22.2 14 20.3 
Tumour malignancy      
Malignant 44 58.7 49 71.0 
Benign 31 41.3 20 29.0 
Type of tumour      
Meningioma 16 21.6 9 13.2 
Glioblastoma 10 13.5 14 20.6 
Astrocytoma 11 14.9 11 16.2 
Pituitary adenoma 8 10.8 5 7.4 
Oligodendroglioma 7 9.7 8 11.8 
Other 21 10.9 18 26.5 
Don’t know 1 1.4 3 4.4 
Treatments undertaken**      
Chemotherapy 16 23.5 31 44.3 
Radiotherapy 44 64.7 57 81.4 
Surgery 53 77.9 55 78.6 
Other treatment 2 2.9 4 5.7 
No treatment 2 2.9 0 0.0 
Time since last treatment      
5 years or less 53 73.6 48 75.0 
>5 to 10 years 10 13.9 8 12.5 
>10 years 9 12.5 8 12.5 
*Tumour and treatment characteristics reported by patients and carers do not correspond one to one as 
within some households only the patients or only the carers participated in the survey. Numbers within 
categories vary slightly due to missing responses. 
** Multiple responses possible 
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Table 2 Quality of life, HADS anxiety and depression scores amongst 75 patients and 70 carers 
 Mean (sd) scores  
Correlation 
coefficient**; p-value 
  Patients*  Carers   
Domain     
Physical Well-Being   18.5 (6.4) 23.3 (3.8)  r = 0.19, p = 0.18 
Social/Family Well-Being 20.1 (6.3) 18.3 (7.3)  r = 0.38, p = 0.007 
Emotional Well-Being 16.7 (5.1) 17.5 (5.9)  r = 0.31, p = 0.03 
Functional Well-Being 17.9 (6.7) 17.8 (6.9) r = 0.21, p = 0.15 
Overall score     
Brain tumour specific subscale 61.7 (17.3) NA  NA 
FACT-G 74.6 (18.6) 76.7 (17.7)  r = 0.32, p = 0.03 
FACT-Br 136.0 (32.9) NA  NA 
Other indicators     
Anxiety 8.1 (4.2) 9.2 (4.6)  r = 0.28; 0.04 
% 11+  points  29.8 39.7   
Depression 5.7 (4.9) 5.4 (4.0)  r = -0.32;  0.02 
% 11+  points  17.2 10.3   
Abbreviations: HADS: Hospital Anxiety and Depression Scale, FACT: Functional Assessment of 
Cancer Therapy 
* Patient scores are weighted to the 20-year prevalence of brain tumours in Queensland 
** Pearson correlation of patient and carer pairs from 53 households 
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Table 3 Correlation between quality of life and anxiety and depression for 75 patients with a brain tumour and for 70 carers of patients with a 
brain tumour (carers results marked in bold) 
 
 PWB SWB EWB FWB FACT-G Anxiety Depression 
PWB  0.34 0.59 0.73 0.85 -0.64 -0.78 
SWB 0.28  0.27 0.48 0.68 -0.34 -0.33 
EWB 0.58 0.13  0.52 0.73 -0.72 -0.54 
FBW 0.49 0.47 0.46  0.88 -0.58 -0.81 
FACT-G 0.71 0.69 0.69 0.84  -0.72 -0.79 
Anxiety -0.64 -0.22 -0.77 -0.52 -0.70   0.51 
Depression -0.67 -0.27 -0.54 -0.71 -0.71 0.66  
Note: Bold figures represent scores derived from carers 
Need Abbreviations PWB = Physical Well-being, SWB = Social Well-being, EWB = Emotional Well-being, FWB = Functional Well-being, FACT-G = 
Functional Assessment of Cancer Therapy, Anxiety = Anxiety Subscale from the Hospital Anxiety and Depression Scale, Depression = Depression Subscale 
from the Hospital Anxiety and Depression Scale.
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Table 4 Adjusted multivariate logistic regression analysis of factors predicting low quality of 
life* in patients with a brain tumour and their carers 
 
 PATIENTS CARERS 
 Adjusted Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI) 
Gender     
Men 1.00   1.00  
Women 7.76  (2.14-28.1)  1.09  (0.31-3.82) 
Age    
18-49 1.00   1.00  
50+ 4.90  (4.89-134.9)  0.72  (0.21-2.45) 
Diagnosis    
Oligodendroglioma 1.00   1.00  
Glioblastoma 1.41  (0.19-10.4)  3.94  (0.60-25.6) 
Astrocytoma 1.36  (0.22-8.37)  0.31  (0.04-2.44) 
Other benign 0.19  (0.10-3.59)  0.70  (0.11-4.31) 
Other malignant 2.44  (0.43-13.9)  0.78  (0.13-4.75) 
 
Abbreviations: CI = Confidence Interval. 
The variables in the model are adjusted for all other factors. 
* Low quality of life was defined as a score one standard deviation or more below the mean normative 
score derived from the Queensland General Population
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